Advertisement

Content Analysis of Off-label Drug Use: Reporting Print Media Coverage

Abstract

Objective

Assess the newspaper coverage of off-label drug use from the years 1990 to 2010.

Methods

News articles from the top six selling national newspapers were studied. Variables of interest were the number of articles published, article themes, headline and content tone, concerns and benefits discussed with offlabel use, drugs discussed, and primary indi-viduals interviewed for the article.

Results

The number of articles published on off-label drug and device use steadily increased over the period of the study. The key themes discussed in these articles were concerns over safety and effcacy (45.8%) and benefits of off-label prescribing (25.9%). The overall tone of the articles was often negative toward offlabel use (40.4% of articles).

Conclusion

Overall, the tone and coverage of off-label medication and device usage was more negative than positive, focusing more on concerns than on benefits. Nevertheless, there did not appear to be any impartial or systematic media bias against the practice.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    IMS Health. Press room: IMS Health reports U.S. prescription sales grew 5.1 percent in 2009. April 1, 2010. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=d690a27e9d5b7210VgnVCM100000ed152ca2RCRD&cpsextcurrchannel=1 (accessed: January 21, 2011).

  2. 2.

    Radley D, Finkelstein S. Off-label prescribing among offce-based physicians. Arch Intern Med. 2006;166:1021–1026.

  3. 3.

    Beck J, Azari E. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J. 1998;53:71–104.

  4. 4.

    Steinman M, Bero L, Chren M, Landefeld C. Nar-rative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284–293.

  5. 5.

    Spielmans G. The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med. 2009;69(1):14–20.

  6. 6.

    Yan J. FDA blamed for poor monitoring of off-label drug promotion. Psychiat News. 2008;43 (18):1–3.

  7. 7.

    Dentzer S. Communicating medical news—pitfalls of health care journalism. N Engl J Med. 2009;360:1–2.

  8. 8.

    Calloway C, Jorgensen C, Saraiya M, Tsui J. A content analysis of news coverage of the HPV vac-cine by U.S. newspapers, January 2002–June 2005. J Women’s Health. 2006;15:803–809.

  9. 9.

    Wells W, Burnett J. Advertising: Principles and Practice. 5th ed. Upper Saddle River, NJ: Prentice Hall; 2000.

  10. 10.

    Sillup G, Porth S. Ethical issues in the pharma-ceutical industry: an anlysis of US newspapers. Int J Pharm Healthcare Marketing. 2008;2(3):163–180.

  11. 11.

    Information Please. Top 100 newspapers in the U.S. March 31, 2006. http://www.infoplease.com/ipea/A0004420.html (accessed July 6, 2008).

  12. 12.

    Holdford D. Content analysis methods for conducting research in social and administrative pharmacy. Res Social Adm Pharm. 2008;4(2):173–181.

  13. 13.

    Brodie M, Brady L, Altman D. Media coverage of managed care: is there a negative bias? Health Affairs. 1998;17(1):9–25.

  14. 14.

    Macnamara J. Media content analysis: uses, benefits and best practice methodology. CARMA. 2006. http://www.carmaapac.com/downloads/Media%20Content%20Analysis%20Research%20Paper.pdf.

  15. 15.

    Roznowski J. A content analysis of mass media stories surrounding the consumer privacy issue 1990–2001. J Interact Marketing. 2003;17(2):53–69.

  16. 16.

    Kaphingst K, Dejong W, Rudd R, Daltroy L. A content analysis of direct-to-consumer television prescription drug advertisements. J Health Comm. 2004;9:515–528.

  17. 17.

    Cassels A. Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. Can Med Assoc J. 2003;168(9).

  18. 18.

    Hochman M, Hochman S, Bor D, McCormick D. News media coverage of medication research: re-porting pharmaceutical company funding and use of generic medication names. JAMA. 2008; 300:1544–1550.

  19. 19.

    Motl S, Timpe E, Eichner S. Evaluation of accuracy of health studies reported in mass media. J Am Pharm Assoc. 2005;45:720–725.

  20. 20.

    Moynihan R, Bero L, Ross-Degnan D et al. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000;342:1645–1650.

  21. 21.

    George P, Stephen J. Ethical issues in the phar-maceutical industry: an analysis on US newspa-pers. Int J Pharm Healthcare Marketing. 2008; 2(3):163.

  22. 22.

    Stebbing C, Kaushal R, Bates D. Pediatric medi-cation safety and the media: what does the public see? Pediatrics. 2006;117:1907–1914.

  23. 23.

    Ryan C. Prime Time Activisim: Media Strategies for Grassroots Organizing. Cambridge, MA: South End Press; 1991.

  24. 24.

    McCombs M. News infuence on our pictures of the world. In: Media Effects: Advances in Theory and Research. Hillsdale, NJ: Erlbaum; 1994:1–16.

  25. 25.

    McCombs M, Shaw D. The agenda setting func-tion of the mass media. Pub Opin Q. 1972;36(2): 176–187.

  26. 26.

    Bartlett C. What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers. Br Med J. 2002;325:81–84.

  27. 27.

    Grilli R. Mass media interventions: effects on health services utilization. Cochrane Database Syst Rev. 2000;CD000389.

  28. 28.

    Howland D, Becker M, Prelli L. Merging content analysis and the policy sciences: a system to dis-cern policy-specifc trends from media reports. Pol Sci. 2006;39:205–231.

  29. 29.

    Lipman A. The FDA and Congress: differing agendas? J Pain Palliat Care Pharmacother. 2010;24(2): 116–117.

  30. 30.

    Tanne J. Congress asks for investigation of FDA resources and staffng. BMJ. 2008;336:525.

  31. 31.

    Kaiser Family Foundation. Kaiser health poll report: public opinion snapshot on health information sources. 2005. http://www.kff.org/kaiserpolls/pomr071805oth.cfm (accessed March 17, 2010).

  32. 32.

    Flanagin A, Metzger M. Perceptions of Internet information credibility. Journalism Mass Commun Q. 2000;77:515–540.

  33. 33.

    Kiousis S. Public trust or mistrust? Perceptions of media credibility in the information age. Mass Commun Soc. 2001;4:381–403.

  34. 34.

    Johnson T, Kaye B. Comparing Internet and tra-ditional sources on media credibility measures. Journalism Mass Commun Q. 1998;75:325–340.

  35. 35.

    Pribble J, Goldstein K, Fowler E, Greenberg M, Noel S, Howell J. Medical news for the public to use? What’s on local TV news. Am J Manag Care. 2006;12(3):170–176.

  36. 36.

    Corbett J, Mori M. Medicine, media, and ce-lebrities: news coverage of breast cancer, 1960–1995. Journalism Mass Commun Q. 1999;76:229–249.

Download references

Author information

Correspondence to David A. Holdford RPh, MS, PhD, FAPhA.

Additional information

The authors report no relevant relationships to disclose.

Graduate student at time of research.

The authors report no relevant relationships to disclose.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Patel, D.A., Joshi, A.D., Holdford, D.A. et al. Content Analysis of Off-label Drug Use: Reporting Print Media Coverage. Ther Innov Regul Sci 45, 787–796 (2011). https://doi.org/10.1177/009286151104500515

Download citation

Key Words

  • Content analysis
  • Off-label drug use
  • Unapproved drug use
  • Off-label prescribing
  • News media